



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Frailty and mortality in patients with COVID-19

The COVID-19 in Older People (COPE) study by Jonathan Hewitt and colleagues¹ supports the use of the Clinical Frailty Scale (CFS) for prognostication. These findings support our recently published single-center experience.² However, several aspects of this study deserve clarification.

COPE included patients aged between 20 and 101 years old. Frailty is a geriatric concept, although it might originate in midlife, and UK guidelines specify that the CFS should not be applied to younger people.³ Frailty predicted mortality in our exclusively geriatric cohort (≥ 65 years).² Judging from the COPE data, frailty does not appear to be associated with mortality in patients younger than 65 years.

The methods do not specify whether biomarkers were measured on admission or during their hospital stay.¹ In our study, C-reactive protein concentrations at admission were not associated with mortality, with median values less than 40 mg/L in both patients who survived and those who did not.² Could the authors report the median C-reactive protein concentrations in their groups?

Many studies on COVID-19 use Cox proportional hazard models, which consider both mortality and its timing (early or late). I wonder whether such models are appropriate for an acute life-threatening illness. In that regard, I question the validity of mortality on day 7 of treatment in hospital as an appropriate outcome.

Finally, the authors of the COPE study suggest that the CFS could be used for shared decision making. However, CFS by itself has insufficient sensitivity and specificity to be useful in clinical practice.² Indeed, luckily, most frail older adults that have been treated in hospital survive COVID-19. Given that the adjusted hazard ratios in the COPE study are similarly low as in our report, I believe that the

predictive use would be similarly restricted.

I report personal fees from Alexion Pharma, Amgen, Kyowa Kirin, Menarini, Sandoz, Takeda, Union Chimique Belge, and Will-Pharma.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Michaël R. Laurent
michael.laurent@imelda.be

Geriatrics Department, Imelda Hospital, Bonheiden 2820, Belgium; University Hospitals Leuven, Leuven, Belgium

- 1 Hewitt J, Carter B, Vilches-Moraga A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. *Lancet Public Health* 2020; **5**: e444–51.
- 2 De Smet R, Mellaerts B, Vandewinckele H, et al. Frailty and mortality in hospitalized older adults with COVID-19: retrospective observational study. *J Am Med Dir Assoc* 2020; **21**: 928–32.e1.
- 3 National Institute for Health and Care Excellence. COVID-19 rapid guideline: critical care in adults. NICE guideline [NG159]. March 20, 2020. <https://www.nice.org.uk/guidance/ng159> (accessed April 24, 2020)